Large healthcare system evaluation of postoperative moxifloxacin ophthalmic solution cross-reactivity

J Cataract Refract Surg. 2022 Nov 1;48(11):1347-1348. doi: 10.1097/j.jcrs.0000000000001039.

Authors

Kathleen K Adams¹, Sunish Shah

Affiliation

¹ From the University of Connecticut School of Pharmacy, Storrs Mansfield, Connecticut (Adams); Department of Pharmacy, Yale New Haven Health, Department of Pharmacy Services, New Haven, Connecticut (Adams, Shah); Antimicrobial Management Program, University of Pittsburgh Medical Center, Pittsburgh, PA (Shah).

PMID: 36026700
DOI: 10.1097/j.jcrs.0000000000001039

No abstract available

Publication types

Letter

MeSH terms

Anti-Bacterial Agents / therapeutic use
Aza Compounds*
Delivery of Health Care
Fluoroquinolones*
Humans
Moxifloxacin
Ophthalmic Solutions

Substances

Moxifloxacin
Fluoroquinolones
Anti-Bacterial Agents
Ophthalmic Solutions
Aza Compounds